title: Differential expression of FosB, c-Fos, and Zif268 in forebrain regions after acute or chronic L-DOPA treatment in a rat model of Parkinson's disease.
abstract: A study was carried out to examine the effects of acute and chronic L-DOPA treatment on the distribution of the immediate-early gene (IEG) proteins (FosB, c-Fos, and Zif268) in forebrain regions in a unilateral 6-hydroxydopamine (6-OHDA) rat model of Parkinson's disease. During a course of chronic L-DOPA treatment (15 mg/day, 15 days), rats with a 6-OHDA lesion developed abnormal involuntary movements. Compared with the rats in the acute L-DOPA treatment group, those in the chronic treatment group had significantly more FosB-immunopositive cells in the anterior cingulate (Cg) and the dorsolateral caudate-putamen ipsilateral to the lesion and significantly fewer c-Fos-immunopositive cells in the Cg, the nucleus accumbens shell, and the basolateral nucleus of amygdala ipsilateral to the lesion. No significant difference was observed in the number of Zif268-immunopositive cells between the acute and chronic L-DOPA groups. In summary, differential expression of three IEG proteins was observed in the forebrain regions during a course of chronic L-DOPA treatment of 6-OHDA-treated hemiparkinsonian rats.
authors.affiliation: Department of Psychiatry, Faculty of Medicine, University of Miyazaki, 5200 Kihara, Kiyotake-cho, Miyazaki 889-1692, Japan.
authors.forename: Kosuke
authors.initials: K
authors.lastname: Ebihara
authors.forename: Yasushi
authors.initials: Y
authors.lastname: Ishida
authors.forename: Ryuichiro
authors.initials: R
authors.lastname: Takeda
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Abe
authors.forename: Hisae
authors.initials: H
authors.lastname: Matsuo
authors.forename: Keiichi
authors.initials: K
authors.lastname: Kawai
authors.forename: Yasuhiro
authors.initials: Y
authors.lastname: Magata
authors.forename: Toshikazu
authors.initials: T
authors.lastname: Nishimori
mesh_terms: D000208:Acute Disease; D000818:Animals; D002908:Chronic Disease; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D051766:Early Growth Response Protein 1 / Q000378:metabolism*; D005786:Gene Expression Regulation / Q000187:drug effects; D007980:Levodopa / Q000008:administration & dosage*; D008297:Male; D020734:Parkinsonian Disorders / Q000188:drug therapy* / Q000378:metabolism*; D016548:Prosencephalon / Q000187:drug effects / Q000378:metabolism*; D016760:Proto-Oncogene Proteins c-fos / Q000378:metabolism*; D051381:Rats; D017208:Rats, Wistar; D014018:Tissue Distribution; D016896:Treatment Outcome
chemical_list: D051766:Early Growth Response Protein 1; C486110:Egr1 protein, rat; C483820:Fosb protein, rat; D016760:Proto-Oncogene Proteins c-fos; D007980:Levodopa